TipRanks
Go Ultimate55% OFF

CASI Pharmaceuticals (ENM) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Cid-103Antibody Mediated Rejectionphase1AndPhase2RecruitingA Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).May 20, 2026―
Cid-103Chronic Immune Thrombocytopeniaphase1AndPhase2RecruitingA Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaJun 04, 2025
Cid-103Multiple MyelomaPhase ICompletedCID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple MyelomaFeb 08, 2021―
Enmd-2076Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar CarcinomaPhase IICompletedA Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaSep 05, 2014―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Casi Pharmaceuticals, Inc. (CH:ENM) have in its pipeline
CASI Pharmaceuticals CH:ENM is currently developing the following drugs: Cid-103, Enmd-2076. These drug candidates are in various stages of clinical development as the company works toward FDA approval.